Clinical Trial Update: Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating roflumilast in COPD patients already treated with fixed-dose LABA/ICS combinations. Results were posted in January 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Exacerbation of Chronic Obstructive Pulmonary Disease

Drugs mentioned

• ADVAIR DISKUS (fluticasone propionate and salmeterol)
• Roflumilast (roflumilast)
• Symbicort (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: COPD, COPD Exacerbation | Phase 4 | Status: COMPLETED | Results posted: 2017-01-25